Hemant Surgical H1 FY27: revenue +328% YoY to ₹276 Cr, PAT +245% amid margin compression
PAT +245% YoY · revenue +327.7% · margins compressing
₹276.31 Cr
+327.7% YoY
₹18.84 Cr
+245% YoY
6.76%
-1.4pp YoY
₹13.3
Hemant Surgical Industries' consolidated revenue for the half year ended September 30, 2026 (H1 FY27) was ₹276.31 Cr, up 327.7% year-on-year from ₹64.62 Cr in H1 FY26 and up 65.3% half-on-half from ₹167.19 Cr in H2 FY26. Consolidated PAT rose 245.0% YoY to ₹18.84 Cr from ₹5.46 Cr (+48.0% half-on-half from ₹12.73 Cr). Standalone PAT was marginally higher at ₹19.12 Cr (EPS ₹13.49) against consolidated EPS of ₹13.30 — the difference is a ₹55.56 lakh loss at subsidiary Lifesenz Cancer Research Labs, acquired June 1, 2026, which the parent absorbs in full since the minority stake carries no obligation to fund losses under AS-21. There is no street number to grade this against: Hemant Surgical is listed on the BSE SME platform with no sell-side analyst coverage, and neither our records nor public searches turn up formal management guidance or a separate press release/MD&A commentary beyond the statutory board-outcome filing — so this quarter's framing rests entirely on the filed numbers themselves.
Q2 FY-2027 vs prior quarters
Despite the revenue surge, consolidated net margin compressed to 6.76% from 8.16% a year ago, and EBITDA margin (profit before tax plus depreciation and finance cost) fell to roughly 10.7% from 14.9%. The raw-material-plus-inventory cost ratio rose to 77.2% of revenue from 71.9% YoY, consistent with a lower-margin mix as the company executes a large bulk government tender rather than its usual direct/distributor sales. Employee costs rose a more modest 34% YoY (₹6.67 Cr from ₹4.97 Cr) even as revenue grew more than fourfold, reflecting operating leverage on staff costs, while finance costs eased to ₹1.16 Cr from ₹1.95 Cr, helped by debt repayment funded from warrant-conversion proceeds.
The stock went into the print at ₹639.9, up 6.3% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 2 consecutive quarters; revenue is at a 6-quarter high.
The revenue ramp lines up with the ₹264.33 Cr order the company won from the Central Medical Service Society (Ministry of Health and Family Welfare) via purchase orders dated December 2 and 10, 2025, for flat panel detectors, X-ray generators and accessories — precisely the kind of bulk government supply that would show up in this half's topline and pressure the margin mix. Subsidiary Lifesenz Cancer Research Labs, onboarded June 1, 2026, booked its first full stub period of consolidated losses this half, with cumulative losses since acquisition of ₹99.75 lakh against a minority interest of ₹55.56 lakh — both absorbed by the parent.
W1
Residual backlog of the ₹264.33 Cr CMSS order still to be executed beyond H1 FY27 — watch H2 FY27 revenue for a continued elevated run-rate or a step-down.
W2
Raw-material-plus-inventory cost ratio (77.2% of revenue this half vs 71.9% a year ago) — whether it reverts as the order mix normalizes, signalling margin recovery.
W3
Lifesenz Cancer Research Labs subsidiary — cumulative losses of ₹99.75 lakh since the June 1, 2026 acquisition; watch for breakeven in H2 FY27 since the parent bears these losses in full.